美通社

2024-09-16 15:35

Akeso's Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety at ESMO 2024

HONG KONG, Sept. 16, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) published the phase 2 results from its ivonescimab in combination with chemotherapy as a first-line (1L) treatment for triple-negative breast cancer (TNBC). The preliminary data, with only a 10-month median follow-up, revealed that the ivonescimab combination regimen demonstrated excellent efficacy and a favorable safety profile in 1L TNBC. Professor Wang Xiaojia from Zhejiang Provincial Cancer Hospital, a co-primary investigator of the study, presented the findings orally at the conference.

As of May 31, 2024, a total of 30 patients with locally advanced unresectable or metastatic TNBC were enrolled. 80% of patients had a PD-L1 combined positive score (CPS) <10, and 60% of patients had previously received taxane-based neoadjuvant or adjuvant therapy (a proportion higher than that observed in similar studies involving targeted drugs).

Although the follow-up period is relatively short and the data are not yet mature, the study still demonstrates that the ivonescimab combination regimen demonstrates excellent progression-free survival (PFS) benefits for TNBC patients, with safety consistent with previous ivonescimab-related studies.

  • Ivonescimab combination regimen demonstrated high efficacy in tumor response and disease control, with an objective response rate (ORR) of 72.4% and a disease control rate (DCR) of 100%, including a complete response (CR) rate of 6.9%.
    • As of the latest update, five additional patients have achieved partial response (PR) (Among them, four newly evaluable patients all achieved a PR, and one patient who previouly had stable disease also achieved a PR ), leading to an adjusted ORR of approximately 78.8% and DCR of 100%.
  • Ivonescimab combination regimen showed a promising trend towards improved long-term survival benefits, with a median progression-free survival (PFS) of 9.3 months (6.24 months -NE), and a 6-month PFS rate of 73.3%.
  • In the PD-L1 CPS≥10 population, the ORR was 83.3%, and the median PFS was not yet reached.
  • In the PD-L1 CPS <1 population, the ORR was 86.7%, with a median PFS of 9.3 months (5.26 months-NE).
    • As of the latest update, two additional patients in the PD-L1 CPS <1 group have achieved PR, resulting in an adjusted ORR of 88.2%.
  • In the PD-L1 CPS <10 population, the ORR was 69.6%, with a median PFS of 9.3 months (5.55 months-NE).
    • As of the latest update, five additional patients in this group have achieved PR, leading to an adjusted ORR of approximately 77.8%.
  • Ivonescimab combined with chemotherapy as a first-line treatment for TNBC exhibited an acceptable safety profile. The most common treatment-related adverse events (TRAEs) were predominantly grade 1-2 and manageable, consistent with previous studies. There were no TRAEs that led to permanent treatment discontinuation or death.

 

source: Akeso, Inc.

【你點睇?】你認為政府是否需要對網約車平台進行更嚴格的規管,以保障的士業界的利益嗎?► 立即投票

人氣文章
最近7天
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
3
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
4
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
5
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
6
一本萬利 | 2025年的五個「勿」(有片)
7
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
8
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
9
電騙 | 黃俊碩:多管齊下,防治內地留學生受騙
10
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
11
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
12
洪灝專訪 | 淘寶衝擊巨大,港樓價未反映大周期拐點(有片)
13
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
14
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
15
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
16
【FOCUS】螺絲殼裏做道場,DeepSeek致勝啟示
17
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
18
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
19
DeepSeek推出即上蘋果中國區榜首,能力直追OpenAI
20
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
21
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
22
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
23
港股 | 蕭猷華:春節假後,恒指逐步上望21000點
24
特朗普就職 | 特朗普上台後行動列表
25
馬斯克明拆特朗普台,指其星際之門計劃「假大空」
26
【FOCUS】侵侵呼籲全球「降息」,日銀祭18年最激進加息
27
高息定存 | 富邦一周港元定存高達9.88厘,一個月4.88厘
28
神州經脈 | 特朗普或與華討論關稅,人民幣大漲,滬指連升兩周
29
港股 | 蕭猷華:恒指本周目標20500點
30
【FOCUS】MAGA第一擊落子AI,中國大模型實力「黑馬」
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

etnet榮獲第六屆國際信息商會議「最佳信息商」白金獎

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

貨幣攻略

大國博弈

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老